Petrelintide vs Cagrilintide
How they differ
- FDA status, the same for both (In clinical trials). Petrelintide: In clinical trials; not FDA-approved.1,2,3 Cagrilintide: In clinical trials; not FDA-approved.4,5,6
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Petrelintide | Cagrilintide |
|---|---|---|
| What it is | An investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,7,8 | An investigational long-acting amylin analogue from Novo Nordisk, also known as AM833.4,9 |
| FDA status | In clinical trials In clinical trials; not FDA-approved1,2,3 Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.2,3,10 | In clinical trials In clinical trials; not FDA-approved4,5,6 Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.6 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.11 | Not among the six peptides the policy lists.11 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | ||
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 3ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 4Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 5ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 6FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 7ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 8Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 ↗
Diabetes, Obesity and Metabolism · Official source · Source checked November 14, 2026
- 9Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial (2021) · PMID 34798060 ↗
The Lancet · Official source · Source checked November 14, 2026
- 10ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 11HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 12Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 16, 2026
- 13ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 14Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, 2025) · PMID 40544433 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 15ClinicalTrials.gov record NCT07745504 · retained source version 2026-08-04:624035118e08abe47d4c56faae694b0047f077f295c17f9043520d41dcfc3f70 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026